Lamprecht Alf, Yamamoto Hiromitsu, Takeuchi Hirofumi, Kawashima Yoshiaki
Laboratory of Pharmaceutical Engineering, Gifu Pharmaceutical University, Gifu, Japan.
Eur J Pharm Biopharm. 2004 Jul;58(1):37-43. doi: 10.1016/j.ejpb.2004.01.003.
Recently, tacrolimus was shown to be effective in mitigating inflammatory bowel disease (IBD). In the treatment of IBD, oral drug delivery using pH-dependent polymers is one of the most successful therapeutic strategies. Eudragit P-4135F, a pH-sensitive polymer for colonic delivery was used to prepare tacrolimus microparticles using an oil/oil emulsification or an oil/water emulsification technique combined with a solvent extraction or evaporation step. Although the pH-dependent drug release was similar for all types of microspheres, it was generally found that encapsulation rates of oil/water systems (extraction 38.8 +/- 9.4%; evaporation 56.3 +/- 1.9%) were superior to the oil/oil emulsification (4.8 +/- 0.4%). Eudragit P-4135F was found to limit drug leakage at pH 6.8 to levels lower than 10% within 6 h. At pH 7.4, almost immediate release (within 30 min) was observed. From differential scanning calorimetry and X-ray analyses, the drug inside the polymeric microsphere matrix was concluded to be present in a molecular dispersion. Generally, all formulations proved their applicability in vitro as a promising device for pH-dependent colonic delivery of tacrolimus, however, the oil/water technique was found to be superior to the oil/oil approach and among them solvent evaporation seemed to be more advisable, due to the higher encapsulation rate.
最近,已证明他克莫司在减轻炎症性肠病(IBD)方面有效。在IBD的治疗中,使用pH依赖性聚合物的口服给药是最成功的治疗策略之一。Eudragit P - 4135F是一种用于结肠给药的pH敏感聚合物,采用油/油乳化或油/水乳化技术结合溶剂萃取或蒸发步骤来制备他克莫司微粒。尽管所有类型微球的pH依赖性药物释放相似,但通常发现油/水系统的包封率(萃取法为38.8±9.4%;蒸发法为56.3±1.9%)优于油/油乳化法(4.8±0.4%)。发现Eudragit P - 4135F可将pH 6.8时的药物泄漏限制在6小时内低于10%的水平。在pH 7.4时,观察到几乎立即释放(30分钟内)。通过差示扫描量热法和X射线分析得出,聚合物微球基质内的药物以分子分散形式存在。总体而言,所有制剂在体外均证明其作为他克莫司pH依赖性结肠给药的有前景装置的适用性,然而,发现油/水技术优于油/油方法,并且在它们之中,由于包封率更高,溶剂蒸发似乎更可取。